Pharmacotherapy of obsessive-compulsive disorder: Overview and treatment-refractory strategies

Obsessive-Compulsive Disorder: Contemporary Issues in Treatment

Volumn , Issue , 2017, Pages 277-302

  Pigott, Teresa A ^a   Seay, Sheila ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85068744668     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4324/9781315561073-28     Document Type: Chapter

References (124)

1. American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington, DC: Author.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3. Ananth, J. (1986). Clomipramine: An antiobsessive drug. Canadian Journal of Psychiatry, 31, 253-258.
4. Ananth, J., Pecknold, J., van den Steen, N., & Engelsmann, F. (1981). Double-blind study of clomipramine and amitriptyline in obsessive neurosis. Progress in Neurovsychopharmacology, 5, 257-262.
5. Ananth, J., Solyom, L., & Solyom, C. (1975). Doxepin in the treatment of obsessive-compulsive disorder. Psychosomatics, 16, 185-187.
6. Asberg, M., Thoren, P., & Bertilsson, L. (1982). Clomipramine treatment of obsessive-compulsive disorder: Biochemical and clinical aspects. Psychovharmacology Bulletin, 18(3), 13-21.
7. Austin, L., Lydiard, R., Fossey, M., Zealberg, J., Laraia, M., & Ballenger, J. (1990). Panic and phobic disorders in patients with OCD. Journal of Clinical Psychiatry, 52(11), 456-458.
8. Bacher, N. (1990). Clonazepam treatment of OCD. Journal of Clinical Psychiatry, 51, 168-169.
9. Baer, L. (1994). Factor analysis of symptom subtypes of obsessive-compulsive disorder and their relation to personality and tic disorders. Journal of Clinical Psychiatry, 55, 18-23.
10. Barr, L., Goodman, W., Price, L., McDougle, C, & Charney, D. (1992). The serotonin hypothesis of obsessive-compulsive disorder: Implications of pharmacologic challenge studies. Journal of Clinical Psychiatry, 53(4), 17-28.
11. Benfield, D., Harris, C, & Luscombe, D. (1980). Some psychopharmacological aspects of desmethylclomipramine. Postgraduate Medicine, 56(1), 13-18.
12. Benfield, P., & Ward, A. (1986). Fluvoxamine: A review of its pharmacokinetic properties and therapeutic efficacy in depression. Drugs, 32, 313-334.
13. Bodkin, A., & White, K. (1989). Clonazepam in the treatment of CCD. Journal of Clinical Psychiatry, 50, 265-266.
14. Browne, M., Horn, E., & Jones, T. (1993). The benefits of clomipramine-fluoxetine combination in OCD. Canadian Journal of Psychiatry, 38, 242-243.
15. Carrasco, J., Hollander, E., Schneier, F., & Liebowitz, M. (1992). Treatment outcome of OCD with comorbid social phobia. Journal of Clinical Psychiatry, 53, 387-391.
16. Chouinard, G., Belanger, M., Beauclair, L., Sultan, S., & Murphy, B. (1996). Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant in OCD resistant to SSRIs: A case report. Progress in Neuropsychopharmacology and Biological Psychiatry, 20, 1067-1079.
17. Clomipramine Collaborative Study Group (1991). Clomipramine in the treatment of patients with OCD. Archives of General Psychiatry, 48, 730-738.
18. Crewe, H., Lennard, M., Tucker, G., Woods, F., & Haddock, R. E. (1992). The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 activity in human liver microsomes. British Journal of Clinical Pharmacology, 34, 262-265.
19. Croisile, B., Tourniaire, D., Confavreux, C, Trillet, M., & Aimard, G. (1989). Bilateral damage to the head of the caudate nuclei. Annals of Neurology, 25, 313-314.
20. Deltito, J. (1994). Valproate pretreatment for the difficult to treat patient with OCD. Journal of Clinical Psychiatry, 55, 500.
21. DeVane, C. (1994). Pharmacogenetics and drug metabolism of newer antidepressant agents. Journal of Clinical Psychiatry, 55(12), 38-45.
22. DeVeaugh-Geiss, J., Katz, R., Landau, P., Goodman, W., & Rasmussen, S. (1990). Clinical predictors of treatment response in CCD: Exploratory analyses from multi-center trials of clomipramine. Psychovharmacology Bulletin, 26, 54-59.
23. DeVeaugh-Geiss, J., Landau, P., & Katz, R. (1989). Preliminary results from a multi-center trial of clomipramine in OCD. Psychovharmacology Bulletin, 25(2), 36-40.
24. Dominguez, R. (1992). Serotonergic antidepressants and their efficacy in CCD. Journal of Clinical Psychiatry, 53(10), 56-59.
25. Dupont, R. L., Rice, D. P., Shiraki, S., & Rowland, C. R. (1995). Pharmacoeconomics: Economic costs of CCD. Medical Interface, 4, 102-109.
26. Erzegovesi, S., Rhonchi, P., & Smeraldi, E. (1992). 5-HT2 receptor and fluvoxamine effect in OCD. Human Psychovharmacology, 7, 287-289.
27. Feder, R. (1988). Lithium augmentation of clomipramine. Journal of Clinical Psychiatry, 49, 458.
28. Flament, M., & Bisserbe, J. C. (1997). Pharmacologic treatment of OCD: Comparative studies. Journal of Clinical Psychiatry, 58(12), 18-22.
29. Flament, M., Rapaport, J., Murphy, D., Lake, C, & Berg, C. (1987). Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Archives of General Psychiatry, 44, 219-225.
30. Foa, E., & Kozak, M. (1995). DSM-LV field trial: Obsessive-compulsive disorder. American Journal of Psychiatry, 152(1), 90-96.
31. Fontaine, R., & Chouinard, G. (1989). Fluoxetine in the longterm maintenance treatment of OCD. Psychiatric Annals, 19, 88-91.
32. Freeman, C, Trimble, M., Deakin, J., Stokes, T., & Ashford, J. (1994). Fluvoxamine versus clomipramine in the treatment of OCD: A multi-center, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry, 55, 301-305.
33. Frenkel, A., Rosenthal, J., Nezu, A., & Winston, A. (1990). Efficacy of long-term fluoxetine treatment of OCD. Mf. Sinai Journal of Medicine, 57(6), 348-352.
34. Golden, R., Morris, J., & Sack, D. (1988). Combined lithium-tricyclic treatment of OCD. Biological Psychiatry, 23, 181-185.
35. Goodman, W., Kozak, M., Liebowitz, M., & White, K. (1996). Treatment of OCD with fluvoxamine: A multicentre, double-blind, placebo-controlled trial. International Journal of Clinical Psychopharmacology, 11, 21-30.
36. Goodman, W., McDougle, C, & Price, L. (1992). Pharmacotherapy of obsessive-compulsive disorder. Journal of Clinical Psychiatry, 53(4), 29-37.
37. Goodman, W., & Price, L. (1990). Rating scales for OCD. In M. Jenike, L. Baer, & W. Minichiello (Eds.), Obsessive-compulsive disorders: Theory and management (pp. 154-166). St. Louis, MO: Mosby Year Book.
38. Goodman, W., Price, L., Rasmussen, S., Mazure, C, Delgado, P., Heninger, G. R., & Charney, D. S. (1989). The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): II. Validity. Archives of General Psychiatry, 46, 1012-1016.
39. Goodman, W. K, Price, L. H., Rasmussen, S. A., Delgado, P. L., Heninger, G. R., & Charney, D. S. (1989). Efficacy of fluvoxamine in OCD: A double-blind comparison with placebo. Archives of General Psychiatry, 46, 36-42.
40. Goodman, W. K., Price, L. H., Rasmussen, S. A., Mazure, C, Fleischmann, R. L., Hill, C. L., Heninger, G. R., & Charney, D. S. (1989). The Yale-Brown Obsessive Compulsive Scale (Y-BOCS): I. Development, use, and reliability. Archives of General Psychiatry, 46, 1006-1011.
41. Grady, T. A., Pigott, T. A., L’Heureux, F., Hill, J. L., Bernstein, S. E., & Murphy, D. L. (1993). A double-blind study of adjuvant buspirone hydrochloride in fluoxetine-treated patients with OCD. American Journal of Psychiatry, 150, 819-821.
42. Greist, J., Chouinard, G., DuBoff, E., Halaris, A., Kim, S., Koran, L., Liebowitz, M., Lydiard, R., Rasmussen, S., & White, K. (1995). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with OCD. Archives of General Psychiatry, 52, 289-295.
43. Greist, J., Jefferson, J., Kobak, K., Chouinard, G., DuBoff, E., Halaris, A., Kim, S., Koran, L., Liebowitz, M., & Lydiard, R. (1995). A 1-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of OCD. International Journal of Clinical Psychophar-macology, 10, 57-65.
44. Greist, J., Jefferson, J., Kobak, K., Katzelnick, D., & Serlin, R. (1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: A meta-analysis. Archives of General Psychiatry, 52, 53-60.
45. Hall, H., & Ogren, S. (1981). Effects of antidepressant drugs on different receptors in the rat brain. European Journal of Pharmacology, 70, 393-407.
46. Hermesh, H., Aizenberg, D., & Munitz, H. (1990). Trazodone treatment in clomipramine-resistant OCD. Clinical Neuropharmacology, 13, 322-328.
47. Hewlett, W., Vinogradov, S., & Agras, W. (1990). Clonazepam treatment of obsessions and compulsions. Journal of Clinical Psychiatry, 51, 158-161.
48. Hewlett, W., Vinogradov, S., & Agras, W. (1992). Clomipramine, clonazepam, and clonidine treatment of OCD. Journal of Clinical Psychopharmacology, 12, 420-430.
49. Hollander, E., DeCaria, C, Schneider, F., Schneier, F., Schneier, H., Liebowitz, M., & Klein, D. (1990). Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Journal of Clinical Psychiatry, 51, 119-123.
50. Hollander, E., Fay, M., & Liebowitz, M. (1988). Clonidine and clomipramine in OCD. American Journal of Psychiatry, 145, 388-389.
51. Hollander, E., & Liebowitz, M. (1988). Augmentation of antiobsessional treatment with fenfluramine. American Journal of Psychiatry, 145, 1314-1315.
52. Hollander, E., Mullen, L., DeCaria, C, Skodol, A., Schneier, F., Liebowitz, M., & Klein, D. (1991). OCD, depression, and fluoxetine. Journal of Clinical Psychiatry, 52, 418-422.
53. Hollander, E., Schiffman, E., Cohen, B., River Stein, A., Rosen, W., Gorman, J., Fyer, A., Papp, L., & Liebowitz, M. (1990). Signs of central nervous system dysfunction in obsessive-compulsive disorder. Archives of General Psychiatry, 48, 278-279.
54. Howland, R. (1991). Lithium augmentation of fluoxetine in the treatment of OCD and major depression: A case report. Canadian Journal of Psychiatry, 36, 154-155.
55. Insel, T., Mueller, E., Alterman, I., Linnoila, M., & Murphy, D. (1985). Obsessive-compulsive disorder and serotonin: Is there a connection? Biological Psychiatry, 20, 1174-1188.
56. Insel, T., Murphy, D., Cohen, R., Alterman, I., Kilts, C, & Linnoila, M. (1983). OCD: A double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry, 40, 605-612.
57. Jacobsen, E. (1995). Risperidone for refractory OCD (case report). Journal of Clinical Psychiatry, 56, 423-429.
58. Jain, V., Swinson, R., & Thomas, J. (1970). Phenelzine in obsessional neurosis. British Journal of Psychiatry, 117, 237-238.
59. Jenike, M. (1982). Use of monoamine oxidase inhibitors in OCD. British Journal of Psychiatry, 140, 159.
60. Jenike, M. (1992). Pharmacologic treatment of obsessive-compulsive disorder. Psychiatric Clinics of North America, 15, 895-919.
61. Jenike, M., & Baer, L. (1988). Buspirone in OCD: An open trial. American Journal of Psychiatry, 145, 1285-1286.
62. Jenike, M., Baer, L., & Buttolph, L. (1991). Buspirone augmentation of fluoxetine in patients with OCD. Journal of Clinical Psychiatry, 52, 13-14.
63. Jenike, M. A., Baer, L., & Greist, J. H. (1990). Clomipramine versus fluoxetine in obsessive-compulsive disorder: A retrospective comparison of side effects and efficacy. Journal of Clinical Psychopharmacology, 10, 122-124.
64. Jenike, M., Hyman, S., Baer, L., Holland, A., Minichiello, W., Buttolph, L., Summergrad, P., Seymour, R., & Ricciardi, J. (1989). A controlled trial of fluvoxamine in OCD: Implications for a serotonergic theory. American Journal of Psychiatry, 147, 1209-1215.
65. Jenike, M., & Rauch, S. (1994). Managing the patient with treatment-resistant obsessive-compulsive disorder: Current strategies. Journal of Clinical Psychiatry, 55, 11-17.
66. Jenike, M., Surman, O., Cassem, N., Zusky, P., & Anderson, W. (1983). Monoamine oxidase inhibitors in OCD. Journal of Clinical Psychiatry, 44, 131-132.
67. Judd, F., Chua, P., Lynch, C, & Norman, T. (1991). Fenfluramine augmentation of clomipramine treatment of OCD. Australian and New Zealand Journal of Psychiatry, 25, 412-414.
68. Karno, M., Golding, J., Sorenson, S., & Burnam, M. (1988). The epidemiology of obsessive-compulsive disorder in five U.S. communities. Archives of General Psychiatry, 45, 1094-1099.
69. Kasvikis, Y., & Marks, I. (1988). Clomipramine in obsessive-compulsive ritualizers treated with exposure therapy: Relations between dose, plasma levels, outcome, and side effects. Psychopharmacology, 95, 113-118.
70. Katz, R., DeVeaugh-Geiss, J., & Landau, P. (1990). Clomipramine in OCD. Biological Psychiatry, 28(5), 401-14.
71. Kettle, P., & Marks, I. (1986). Neurological factors in obsessive-compulsive disorder: Two case reports and a review of the literature. British Journal of Psychiatry, 149, 315-319.
72. Kim, S. (1987). Trazodone in the treatment of OCD. Journal of Clinical Psychovharmacology, 7, 278-288.
73. Koe, B., Weissman, A., Welch, W., & Browne, R. G. (1983). Sertraline, a new uptake inhibitor with selectivity for serotonin. Journal of Pharmacology and Experimental Therapeutics, 226, 686-670.
74. Koizumi, H. (1985). Obsessive-compulsive symptoms following stimulants. Biological Psychiatry, 20, 1332-1333.
75. Koran, L., McElroy, S., Davidson, J., Rasmussen, S., Hollander, E., & Jenike, M. (1996). A double-blind, multicenter comparison of fluvoxamine and clomipramine in patients with OCD. Journal of Clinical Psychopharmacology, 16, 121-129.
76. Leonard, H., Swedo, S., Lenane, M., Rettew, D., Cheslow, D., Hamburger, S., & Rapaport, J. (1991). A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry, 48, 922-927.
77. Leonard, H., Swedo, S., Rapoport, J., Coffey, M., & Cheslow, D. (1988). Treatment of childhood obsessive-compulsive disorder with clomipramine and desmethyl-imi-pramine: A double-blind crossover comparison. Psychopharmacology Bulletin, 24, 43-45.
78. Levine, R., Hoffman, J., Knepple, E., & Kenin, M. (1989). Long-term fluoxetine treatment of a large number of obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 9, 281-283.
79. Lipsedge, M., & Prothero, W. (1987). Clonidine and clomipramine in OCD. American Journal of Psychiatry, 144, 965-966.
80. Lydiard, R. (1986). OCD successfully treated with trazodone. Psychsomatics, 27, 858-859.
81. Markovitz, P., Stagno, S., & Calabrese, J. (1990). Buspirone treatment of fluoxetine in OCD. American Journal of Psychiatry, 147, 798-800.
82. Mavissakalian, M., Jones, B., Olson, S., & Perel, J. M. (1990). Clomipramine in obsessive-compulsive disorder: Clinical response and plasma level. Journal of Clinical Psychopharmacology, 5, 207-212.
83. McDougle, C, Fleischmann, R., Epperson, C, Wasylink, S., Leckman, J., & Price, L. (1995). Risperidone addition in fluvoxamine-refractory OCD: Three cases. Journal of Clinical Psychiatry, 56, 526-528.
84. McDougle, C, Goodman, W., Leckman, J., Holzer, J., Barr, L., McCance-Katz, E., Heninger, G., & Price, L. (1993). Limited therapeutic effect of the addition of buspirone in fluvoxamine-refractory OCD. American Journal of Psychiatry, 150, 647-649.
85. McDougle, C, Goodman, W., Leckman, J., Lee, N, Heninger, G., & Price, L. (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: A double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 51, 302-308.
86. McDougle, C, Price, L., Goodman, W., Charney, D., & Heninger, G. (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy. Journal of Clinical Psychopharmacology, 11, 175-184.
87. Montgomery, S. (1980). Clomipramine in obsessional neurosis. Pharmacological Medicine, 1, 189-192.
88. Montgomery, S., Mclntyre, A., Osterheider, M., Sarteschi, P., Zitterl, W., Zohar, J., Birkett, M., & Wood, A. (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R OCD. European Neuropsychopharmacology, 3(2), 143-152.
89. Nierenberg, A., & Cole, J. (1992). Antidepressant adverse drug reactions. Journal of Clinical Psychiatry, 52(6), 40-47.
90. Pato, M., Hill, J., & Murphy, D. (1990). A clomipramine dosage reduction study in the course of long-term treatment of OCD patients. Psychopharmacology Bulletin, 26, 211-214.
91. Pato, M. T., Pigott, T. A., Hill, J. L., Grover, G. N., Bernstein, S. E., & Murphy, D. L. (1991). Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. American Journal of Psychiatry, 148, 127-129.
92. Pato, M., Zohar-Kadouch, R., Zohar, J., & Murphy, D. (1988). Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. American Journal of Psychiatry, 145, 1521-1525.
93. Piccinelli, M., Pini, S., Bellantuono, C, & Wilkinson, G. (1995). Efficacy of drug treatment in OCD: A meta-analytic review. British Journal of Psychiatry, 166, 424-443.
94. Pigott, T. A. (1996). OCD: Where the serotonin selectivity story begins. Journal of Clinical Psychiatry, 57, 11-20.
95. Pigott, T. A., L’Heureux, F., Bernstein, S. E., Grover, G. N., Dubbert, B., Hill, J. L., & Murphy, D. L. (1992, May). A controlled comparison of clomipramine and m-chlorophenylpiperazine in patients with OCD. Paper presented at the NCDEU Annual Meeting, Key Biscayne, FL.
96. Pigott, T., L’Heureux, F., Bernstein, S., Rubenstein, C, Dubbert, B., & Murphy, D. (1992). A controlled trial of adjuvant clonazepam in clomipramine and fluoxetine treated patients with OCD. In 145th Annual American Psychiatric Association Meeting, NR 144 (p. 82). Washington, DC: American Psychiatric Press.
97. Pigott, T., L’Heureux, F., Dubbert, B., Bernstein, S., & Murphy, D. (1994). Obsessive-compulsive disorder: Comorbid conditions. Journal of Clinical Psychiatry, 55(10), 15-27.
98. Pigott, T. A., L’Heureux, F., Hill, J. L., Bihari, K., Bernstein, S. E., & Murphy, D. L. (1992). A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated OCD patients. Journal of Clinical Psychopharmacology, 12, 11-18.
99. Pigott, T., L’Heureux, F., & Murphy, D. (1993, March). Pharmacological approaches to treatment-resistant OCD patients. Paper presented at the 1st International OCD Conference Abstracts, Isle of Capri (Italy) (pp. 123-125).
100. Pigott, T. A., L’Heureux, F., Rubenstein, C. S., Bernstein, S. E., Hill, J. L., & Murphy, D. L. (1992). A double-blind, placebo controlled study of trazodone in patients with obsessive-compulsive disorder. Journal of Clinical Psychopharmacology, 12(3), 156-162.
101. Pigott, T. A., Pato, M. T., Bernstein, S. E., Grover, G. N., Hill, J. L., Tolliver, T. J., & Murphy, D. L. (1990). Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 47, 1543-1550.
102. Pigott, T. A., Pato, M. T., L’Heureux, F., Hill, J. L., Grover, G. N., Bernstein, S. E., & Murphy, D. L. (1991). A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated OCD patients. Journal of Clinical Psychopharmacology, 11(4), 242-248.
103. Pigott, T., & Seay, S. (in press). Comparable efficacy of SSRIs in OCD. Journal of Clinical Psychiatry.
104. Prasad, A. (1984). OCD and trazodone. American Journal of Psychiatry, 141, 612-613.
105. Prasad, A. (1985). Efficacy of trazodone as an antiobsessional agent. Pharmacology, Biochemistry, and Behavior, 22, 347-348.
106. Rasmussen, S. (1984). Lithium and tryptophan augmentation in clomipramine-resistant OCD. American Journal of Psychiatry, 141, 1283-1285.
107. Rasmussen, S., & Eisen, J. (1990). Epidemiology and clinical features of OCD. In M. Jenike, L. Baer, & W. Minichiello (Eds.), Obsessive-compulsive disorders: Theory and management (pp. 10-27). St. Louis, MO: Mosby Year Book.
108. Rasmussen, S., & Eisen, J. (1992). The epidemiology and clinical features of obsessive-compulsive disorder. Psychiatric Clinics of North America, 15(4), 743-758.
109. Rosse, R., Fay-McCarthy, M., Collins, J., Risher-Flowers, D., Alim, T., & Deutsch, S. (1993). Transient compulsive foraging behavior associated with crack cocaine use. American Journal of Psychiatry, 150, 155-156.
110. Simeon, J., Thatte, S., & Wiggins, D. (1990). Treatment of adolescent OCD with a clomipramine-fluoxetine combination. Psychopharmacology Bulletin, 26, 285-290.
111. Smeraldi, E., Erzegovesi, S., Bianchi, I., Bellodi, L., Sciuto, G., & Diaferia, G. (1992). Fluvoxamine versus clomipramine treatment in OCD: A preliminary study. New Trends in Experimental and Clinical Psychiatry, 8, 63-65.
112. Smeraldi, E., Mundo, E., & Erzegovesi, S. (1992). 5-HT3 receptor and antiobsessional effect. Human Psychopharmacology, 7, 291-292.
113. Steiner, M., Bushnell, W., Gergel, I., & Wheadon, D. (1995, May). Long-term treatment and prevention of relapse of OCD with paroxetine. Paper presented at the annual meeting of the American Psychiatric Association, Miami, FL.
114. Stern, R., Marks, I., Wright, J., & Luscombe, D. (1980). Clomipramine: Plasma levels, side effects, and outcome in obsessive-compulsive neurosis. Postgraduate Medical Journal, 56(Suppl. 1), 134-139.
115. Thoren, P., Asberg, M., Bertilsson, L., Mellstrom, B., Sjoqvist, F., & Traskman, L. (1980). Clomipramine treatment of OCD: II. Biochemical aspects. Archives of General Psychiatry, 37, 1289-1294.
116. Thoren, P., Asberg, M., Crohnholm, B., Jornestedt, L., & Trachman, L. (1980). Clomipramine treatment of obsessive-compulsive disorder: I. A controlled clinical trial. Archives of General Psychiatry, 37, 1281-1285.
117. Tollefson, G., Birkett, M., Koran, L., & Genduso, L. (1994). Continuation treatment of OCD: Double-blind and open-label experience with fluoxetine. Journal of Clinical Psychiatry, 55, 69-78.
118. Tollefson, G., Rampey, A., Potvin, J., Jenike, M., Rush, A., Dominguez, R., Koran, L., Shear, M., Goodman, W., & Genduso, L. (1994). A multi-center investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 51(7), 559-567.
119. Vallejo, J., Olivares, J., Marcos, T., Bulbena, A., & Menchon, J. (1992). Clomipramine versus phenelzine in obsessive-compulsive disorder: A controlled clinical trial. British Journal of Psychiatry, 161, 665-670.
120. Volavka, J., Neziroglu, F., & Yaryura-Tobias, J. (1985). Clomipramine and imipramine in obsessive-compulsive disorder. Psychiatry Research, 14, 85-93.
121. Wheadon, D., Bushnell, W., & Steiner, M. (1993, December). A fixed-dose comparison of 20, 40, or 60 mg paroxetine to placebo in the treatment of obsessive-compulsive disorder. Paper presented at the American College of Neuropsychopharmacology (ACNP) annual meeting, San Juan, PR.
122. Wong, D., Bymaster, F., Reid, L., & Threlkeld, P. (1983). Fluoxetine and two other serotonin uptake inhibitors without affinity for neuronal receptors. Biochemistry and Pharmacology, 32, 1287-1293.
123. Yaryura-Tobias, J., & Bhagavan, H. (1977). L-tryptophan in OCD. American journal of Psychiatry, 134, 1298-1299.
124. Zohar, J., & Insel, T. (1987). Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology. Biological Psychiatry, 22, 667-687.